For example, resistance to rituximab and doxorubicin was conferred by CRISPRi of SMARCE1, a known tumor suppressor in DLBCL and other cancers (Shain and Pollack, 2013), and by CRISPRi of CAD, a protein involved in pyrimidine biosynthesis whose knockdown causes S phase arrest (Jost et al., 2017). Here, SMARCE1 is linked to diffuse large B-cell lymphoma.